0 119

Cited 0 times in

Poziotinib for HER2-positive metastatic breast cancer (MBC): Final clinical efficacy and safety results for long-term follow-up of the phase II NOV120101-203 trial

DC Field Value Language
dc.date.accessioned2023-06-02T01:06:30Z-
dc.date.available2023-06-02T01:06:30Z-
dc.date.issued2022-05-
dc.identifier.issn0923-7534-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/194660-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherOxford University Press-
dc.relation.isPartOfANNALS OF ONCOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titlePoziotinib for HER2-positive metastatic breast cancer (MBC): Final clinical efficacy and safety results for long-term follow-up of the phase II NOV120101-203 trial-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorY.H. Park-
dc.contributor.googleauthorK.H. Jung-
dc.contributor.googleauthorJ. Sohn-
dc.contributor.googleauthorK.S. Lee-
dc.contributor.googleauthorJ.H. Kim-
dc.contributor.googleauthorY. Yang-
dc.contributor.googleauthorE. Baek-
dc.contributor.googleauthorH. Han-
dc.contributor.googleauthorS-A. Im-
dc.identifier.doi10.1016/j.annonc.2022.03.195-
dc.relation.journalcodeJ00171-
dc.identifier.eissn1569-8041-
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S0923753422005749-
dc.citation.volume33-
dc.citation.numberSupplement 3-
dc.citation.startPageS207-
dc.citation.endPageS208-
dc.identifier.bibliographicCitationANNALS OF ONCOLOGY, Vol.33(Supplement 3) : S207-S208, 2022-05-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.